[go: up one dir, main page]

WO1998006440A3 - Transformation phenotypique de cellules induite par des sequences guide externes - Google Patents

Transformation phenotypique de cellules induite par des sequences guide externes Download PDF

Info

Publication number
WO1998006440A3
WO1998006440A3 PCT/US1997/014457 US9714457W WO9806440A3 WO 1998006440 A3 WO1998006440 A3 WO 1998006440A3 US 9714457 W US9714457 W US 9714457W WO 9806440 A3 WO9806440 A3 WO 9806440A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
drug
external guide
guide sequences
sensitive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/014457
Other languages
English (en)
Other versions
WO1998006440A2 (fr
Inventor
Garry B Takle
Allan R Goldberg
Shaji T George
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovir Laboratories Inc
Original Assignee
Innovir Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovir Laboratories Inc filed Critical Innovir Laboratories Inc
Priority to AU39844/97A priority Critical patent/AU3984497A/en
Publication of WO1998006440A2 publication Critical patent/WO1998006440A2/fr
Publication of WO1998006440A3 publication Critical patent/WO1998006440A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/126—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes involving RNAse P
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/127—DNAzymes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention se rapporte à un procédé et à des compositions assurant l'apport d'acides nucléiques à des cellules bactériennes. Ledit procédé ne nécessite aucune manipulation des bactéries et convient de ce fait particulièrement à l'apport d'acides nucléiques à des bactéries dans des environnements naturels, notamment au sein de corps animaux. Ledit procédé consiste généralement à conjuguer l'acide nucléique devant être délivré à une porphyrine cationique et à amener le conjugué formé et les cellules bactériennes cible en contact. La porphyrine et l'acide nucléique conjugué sont tous deux assimilés par les cellules bactériennes et l'acide nucléique peut alors avoir un effet biologique sur les cellules. L'invention se rapporte notamment à un procédé permettant de transformer des cellules bactériennes résistantes aux médicaments en cellules sensibles aux médicaments et consistant à apporter des séquences guide externes aux cellules qui favorisent ensuite la coupure des molécules d'ARN contribuant à conférer aux cellules le phénotype de résistance aux médicaments. Le phénotype de résistance aux médicaments des cellules est ensuite transformé en phénotype de sensibilité aux médicaments. Les cellules rendues sensibles aux médicaments peuvent alors être soumises à une pharmacothérapie. L'invention se rapporte également à un procédé et à des compositions permettant de tuer des pathogènes eucaryotes ou de transformer des cellules eucaryotes résistantes aux médicaments en cellules eucaryotes sensibles aux médicaments. Ledit procédé consiste en l'apport de séquences guide externes, de ribozymes ou de vecteurs codant des séquences guide externes ou des ribozymes, à des cellules eucaryotes. Les algues, les protozoaires, les champignons, les myxomycètes et les cellules d'helminthes constituent les cellules eucaryotes cible préférées de la présente invention.
PCT/US1997/014457 1996-08-16 1997-08-15 Transformation phenotypique de cellules induite par des sequences guide externes Ceased WO1998006440A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU39844/97A AU3984497A (en) 1996-08-16 1997-08-15 Phenotypic conversion of cells mediated by external guide sequences

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2367596P 1996-08-16 1996-08-16
US60/023,675 1996-08-16

Publications (2)

Publication Number Publication Date
WO1998006440A2 WO1998006440A2 (fr) 1998-02-19
WO1998006440A3 true WO1998006440A3 (fr) 1998-06-25

Family

ID=21816556

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/014457 Ceased WO1998006440A2 (fr) 1996-08-16 1997-08-15 Transformation phenotypique de cellules induite par des sequences guide externes

Country Status (2)

Country Link
AU (1) AU3984497A (fr)
WO (1) WO1998006440A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9912965D0 (en) * 1999-06-03 1999-08-04 Oxford Biomedica Ltd In vivo selection method

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013740A2 (fr) * 1991-12-31 1993-07-22 Worcester Foundation For Experimental Biology Oligonucleotides antiparasitaires efficaces contre la malaria resistant aux medicaments
WO1994012643A1 (fr) * 1992-12-03 1994-06-09 Unisearch Ltd. Sequence de nucleotides codant la synthetase ii du phosphate de carbamoyle
WO1995027480A1 (fr) * 1994-04-12 1995-10-19 Innovir Laboratories, Inc. Microparticules porteuses d'heme utilisees dans la liberation ciblee de medicaments
WO1996008558A1 (fr) * 1994-09-12 1996-03-21 City Of Hope Modulation de genes resistants aux rayonnements medicamenteux
WO1996021731A2 (fr) * 1995-01-13 1996-07-18 Innovir Laboratories, Inc. Sequences guides externes stabilisees
WO1996021665A1 (fr) * 1995-01-13 1996-07-18 Board Of Regents, The University Of Texas System Turcasarines, nouvelles porphyrines expansees et utilisation desdites substances
WO1997033622A2 (fr) * 1996-03-14 1997-09-18 Innovir Laboratories, Inc. Apport d'acides nucleiques par des porphyrines

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013740A2 (fr) * 1991-12-31 1993-07-22 Worcester Foundation For Experimental Biology Oligonucleotides antiparasitaires efficaces contre la malaria resistant aux medicaments
WO1994012643A1 (fr) * 1992-12-03 1994-06-09 Unisearch Ltd. Sequence de nucleotides codant la synthetase ii du phosphate de carbamoyle
WO1995027480A1 (fr) * 1994-04-12 1995-10-19 Innovir Laboratories, Inc. Microparticules porteuses d'heme utilisees dans la liberation ciblee de medicaments
WO1996008558A1 (fr) * 1994-09-12 1996-03-21 City Of Hope Modulation de genes resistants aux rayonnements medicamenteux
WO1996021731A2 (fr) * 1995-01-13 1996-07-18 Innovir Laboratories, Inc. Sequences guides externes stabilisees
WO1996021665A1 (fr) * 1995-01-13 1996-07-18 Board Of Regents, The University Of Texas System Turcasarines, nouvelles porphyrines expansees et utilisation desdites substances
WO1997033622A2 (fr) * 1996-03-14 1997-09-18 Innovir Laboratories, Inc. Apport d'acides nucleiques par des porphyrines

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GUERRIER-TAKADA C ET AL: "Phenotypic conversion of drug - resistant bacteria to drug sensitivity.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1997 AUG 5) 94 (16) 8468-72., XP002052175 *
GUERRIER-TAKADA, C. ET AL.: "Artificial regulation of gene expression in Escherichia coli by RNase P", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 92, November 1995 (1995-11-01), WASHINGTON US, pages 11115 - 11119, XP002052174 *
HARTMANN R K ET AL: "TOWARDS A NEW CONCEPT OF GENE INACTIVATION: SPECIFIC RNA CLEAVAGE BY ENDOGENOUS RIBONUCLEASE P", BIOTECHNOLOGY ANNUAL REVIEW, vol. 1, 1995, pages 215 - 265, XP000609333 *
HIROSHI KIJIMA ET AL: "THERAPEUTIC APPLICATIONS OF RIBOZYMES", PHARMACOLOGY AND THERAPEUTICS, vol. 68, no. 2, 1995, pages 247 - 267, XP000612090 *
KOBAYASHI H ET AL: "Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme.", CANCER RESEARCH, (1994 MAR 1) 54 (5) 1271-5., XP002062947 *
MERCHAT, M. ET AL.: "Meso-substituted cationic porphyrins as efficient photosensitizers of Gram-positive and Gram-negative bacteria", JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B: BIOLOGY, vol. 32, February 1996 (1996-02-01), pages 153-157, XP002052173 *

Also Published As

Publication number Publication date
WO1998006440A2 (fr) 1998-02-19
AU3984497A (en) 1998-03-06

Similar Documents

Publication Publication Date Title
HUP0004728A1 (hu) Javított eljárás nukleinsav bevitelére többsejtes eukarióta szervezet sejtjeibe és kombinált alkalmazása
EP0827410A4 (fr) Procede d'introduction et d'expression de genes dans des cellules animales
BR9508825A (pt) Transferência de moléculas no citosol de células
DE69906977D1 (de) In liposomen verkapselte nukleinsäurekomplexe
EP1210123A4 (fr) Vecteurs mutationnels d'oligodeoxynucleotides a brin simple
WO2003093469A3 (fr) Procedes d'administration de molecules d'acides nucleiques dans des cellules et evaluation associee
CA2325351A1 (fr) Elaboration non stochastique de vaccins genetiques et d'enzymes
HUP0004589A1 (hu) Javított eljárás nukleinsav bevitelére harántcsikolt izomba és kombinált alkalmazása
WO1997042975A3 (fr) Compositions a base de chitosane et procedes de diffusion d'acides nucleiques dans une cellule
WO2003093449A3 (fr) Procedes d'administration d'acides nucleiques
EP1390049A4 (fr) Preparations de traitement de maladies et de syndromes animaux
WO2005002643A3 (fr) Methode et produits permettant de distribuer des molecules biologiques a des cellules au moyen de nanostructures multicomposants
DE60030970D1 (de) Verfahren und zusammensetzungen für nichtvirale gentherapie zur behandlung von hyperproliferativen krankheiten
WO2002024232A3 (fr) Nouvelles formulations ameliorees de vecteurs de polyethyleneimine/adn aux fins d'un apport genique in vitro
AU2002214596A1 (en) Methods and compositions for nucleic acid delivery
AU2001245637A1 (en) Methods of improving homologous recombination
AU5728399A (en) Method for transformation of animal cells
WO2004108208A3 (fr) Procedes et appareil de conversion de cellules eucaryotes par application de champs electriques et magnetiques
WO2001019966A3 (fr) Isolation de cellules souches derivees de muscle et utilisations associees
WO1998006440A3 (fr) Transformation phenotypique de cellules induite par des sequences guide externes
EP0763205A4 (fr) Sequences d'acides nucleiques regulant l'expression de genes specifiques aux poumons
WO2003059262A3 (fr) Methode et composition de traitement et de prevention d'infections par vih et du sida
DE60002603D1 (de) Phosphor-enthaltende dendrimere als transfektionsagente
AU2002346803A1 (en) Genes encoding for carbon metabolism and energy-producing proteins
Shcherbakova et al. Camptothecin enhances random integration of transfected DNA into the genome of mammalian cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998510090

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA